Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML
Abstract: Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable residual disease (MRD) marker with prognostic significance. Assessment of pr...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924007043 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766273081147392 |
|---|---|
| author | Christian M. Vonk Tim Grob Melissa Rijken François G. Kavelaars Jolinda M. L. Konijnenburg Gert J. Ossenkoppele Markus G. Manz Violaine Havelange Yngvar Fløisand Bob Löwenberg Peter J. M. Valk |
| author_facet | Christian M. Vonk Tim Grob Melissa Rijken François G. Kavelaars Jolinda M. L. Konijnenburg Gert J. Ossenkoppele Markus G. Manz Violaine Havelange Yngvar Fløisand Bob Löwenberg Peter J. M. Valk |
| author_sort | Christian M. Vonk |
| collection | DOAJ |
| description | Abstract: Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable residual disease (MRD) marker with prognostic significance. Assessment of prognostic mNPM1 is included in the European LeukemiaNet recommendations on MRD detection in AML. Because of recent advancements of promising drugs targeting mNPM1 AML, monitoring of mNPM1 MRD has gained interest, and is generally done by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). However, these RT-qPCR assays use complementary DNA (cDNA) as input, are based on gene expression levels of mNPM1, and are generally limited to specific mNPM1 gene variants. The main advantages of next-generation sequencing (NGS) using genomic DNA as input are stability, independence of gene expression levels, and the ability to detect any NPM1 variant in a single assay. Here, we comprehensively investigated the applicability of NGS on DNA to detect mNPM1 MRD in a cohort of 119 (cDNA) and 310 (DNA) patients with mNPM1 AML in complete remission after 2 cycles of induction chemotherapy. We demonstrate high correlations in levels and prognostic value between RT-qPCR/cDNA and NGS/DNA approaches, postulating NGS/DNA as an attractive alternative to RT-qPCR. We report that the 2% mNPM1/ABL1 threshold by RT-qPCR/cDNA corresponds to an NGS/DNA variant allele frequency of 0.01%. The NGS/DNA threshold of >0.01% after 2 cycles of induction chemotherapy identifies significantly more patients with AML with an increased relapse risk than current RT-qPCR/cDNA assays. The prognostic significance of mNPM1 MRD appears greatest in patients with AML with FLT3-internal tandem duplications. |
| format | Article |
| id | doaj-art-baba935dbead4878a791d1290e586fb3 |
| institution | DOAJ |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-baba935dbead4878a791d1290e586fb32025-08-20T03:04:38ZengElsevierBlood Advances2473-95292025-03-01951069107710.1182/bloodadvances.2024014490Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AMLChristian M. Vonk0Tim Grob1Melissa Rijken2François G. Kavelaars3Jolinda M. L. Konijnenburg4Gert J. Ossenkoppele5Markus G. Manz6Violaine Havelange7Yngvar Fløisand8Bob Löwenberg9Peter J. M. Valk10Department of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The NetherlandsDepartment of Medical Oncology and Hematology, Comprehensive Cancer Center Zurich, University and University Hospital Zurich, Zurich, SwitzerlandDepartment of Hematology, Cliniques universitaires Saint-Luc, Brussels, BelgiumCentre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Hematology, Oslo University Hospital, Oslo, NorwayDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; Correspondence: Peter J. M. Valk, Department of Hematology, Erasmus University Medical Center Rotterdam, Nc806, Wytemaweg 80, 3015 CN Rotterdam Z-H, The Netherlands;Abstract: Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable residual disease (MRD) marker with prognostic significance. Assessment of prognostic mNPM1 is included in the European LeukemiaNet recommendations on MRD detection in AML. Because of recent advancements of promising drugs targeting mNPM1 AML, monitoring of mNPM1 MRD has gained interest, and is generally done by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). However, these RT-qPCR assays use complementary DNA (cDNA) as input, are based on gene expression levels of mNPM1, and are generally limited to specific mNPM1 gene variants. The main advantages of next-generation sequencing (NGS) using genomic DNA as input are stability, independence of gene expression levels, and the ability to detect any NPM1 variant in a single assay. Here, we comprehensively investigated the applicability of NGS on DNA to detect mNPM1 MRD in a cohort of 119 (cDNA) and 310 (DNA) patients with mNPM1 AML in complete remission after 2 cycles of induction chemotherapy. We demonstrate high correlations in levels and prognostic value between RT-qPCR/cDNA and NGS/DNA approaches, postulating NGS/DNA as an attractive alternative to RT-qPCR. We report that the 2% mNPM1/ABL1 threshold by RT-qPCR/cDNA corresponds to an NGS/DNA variant allele frequency of 0.01%. The NGS/DNA threshold of >0.01% after 2 cycles of induction chemotherapy identifies significantly more patients with AML with an increased relapse risk than current RT-qPCR/cDNA assays. The prognostic significance of mNPM1 MRD appears greatest in patients with AML with FLT3-internal tandem duplications.http://www.sciencedirect.com/science/article/pii/S2473952924007043 |
| spellingShingle | Christian M. Vonk Tim Grob Melissa Rijken François G. Kavelaars Jolinda M. L. Konijnenburg Gert J. Ossenkoppele Markus G. Manz Violaine Havelange Yngvar Fløisand Bob Löwenberg Peter J. M. Valk Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML Blood Advances |
| title | Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML |
| title_full | Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML |
| title_fullStr | Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML |
| title_full_unstemmed | Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML |
| title_short | Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML |
| title_sort | advantages of a genomic dna based next generation sequencing assay for detection of mutant npm1 measurable residual disease in aml |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924007043 |
| work_keys_str_mv | AT christianmvonk advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT timgrob advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT melissarijken advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT francoisgkavelaars advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT jolindamlkonijnenburg advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT gertjossenkoppele advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT markusgmanz advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT violainehavelange advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT yngvarfløisand advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT boblowenberg advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml AT peterjmvalk advantagesofagenomicdnabasednextgenerationsequencingassayfordetectionofmutantnpm1measurableresidualdiseaseinaml |